Heerlen

• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Not authorised
  2023-503631-18-00 5 Nervous system diseases
• Avelumab Short Maintenance Trial Pending
  2024-512975-11-01 11 urothelial cancer
• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 4 Idiopathic pulmonary fibrosis (IPF)
• Applying Mysimba in patients with weight regain after bariatric surgery Pending
  2024-516645-39-01 11 Obesity
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending
  2025-521950-41-00 5 severe uncontrolled asthma
• Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an … Pending
  2025-524229-41-00 5 Triple negative breast cancer
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting
  2023-504358-36-00 5 2024-10-17 multiple sclerosis
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting
  2023-503699-25-00 5 2024-07-15 Progressive Pulmonary Fibrosis
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting
  2023-503697-21-01 5 2024-06-24 Idiopathic pulmonary fibrosis
• A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting
  2022-501354-10-01 5 2023-06-21 axial spondyloarthritis
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction
• HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting
  2025-523717-29-00 5 2026-04-28 HFpEF or HFmrEF and obesity
• A clinical study of tulisokibart to treat radiographic axial spondyloarthritis (MK-7240-013) Recruiting
  2025-521059-21-00 4 2025-11-25 Radiographic axial spondyloarthritis (as known as ankylosing spondylit
• A study to test whether nerandomilast helps people with lung fibrosis related to rheumatic diseases Recruiting
  2024-512849-17-00 5 2025-11-14 Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Di
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer Recruiting
  2024-515884-69-00 5 2025-07-16 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting
  2024-516834-36-00 5 2025-07-08 Locally recurrent unresectable or metastatic TNBC with tumors expressi
• A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s … Recruiting
  2024-513682-40-01 5 2025-07-04 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
• A research study comparing CDR132L with placebo on the structure and function of the heart in people with heart failure with reduced/mildly … Recruiting
  2024-515797-27-00 4 2025-06-25 Heart Failure with Reduced/Mildly Reducede Ejection Fraction and Left
• StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack – The Randomized Controlled Trial Recruiting
  2024-517343-31-00 6 2025-04-11 Ischemic stroke and transient ischemic attack
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chem … Recruiting
  2023-505773-32-00 10 2025-03-25 Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
• Semaglutide 2.4mg for low responders after bariatric surgery Recruiting
  2022-502164-20-01 6 2025-03-11 obesity

Showing 1–24 of 88 trials